368 related articles for article (PubMed ID: 2148044)
1. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
3. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
6. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
[TBL] [Abstract][Full Text] [Related]
7. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
8. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
9. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
10. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
11. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
[TBL] [Abstract][Full Text] [Related]
12. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
14. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
15. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
16. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
17. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
Zinner NR; Bidair M; Centeno A; Tomera K
Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
[TBL] [Abstract][Full Text] [Related]
18. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
19. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
[TBL] [Abstract][Full Text] [Related]
20. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
